PromotIng Optimal Treatment for Community-acquired PNeumonia in EmErgency Rooms
Key facts
- Who runs it
- Jeffrey Pernica
- Where
- Canada6 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 698 people, planned
- Started
- 15 Apr 2026
- Expected to end
- 15 May 2030
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- The novel care pathway intervention
- Usual Care Alone
- Record updated
- 29 April 2026
Who can take part
- Age
- 6 months to 18 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Children aged 6 month to 18 years presenting to the Emergency Department who are diagnosed with CAP and are well enough to be discharged home (i.e. 'non-severe' CAP) will be eligible. They must have a fever (on exam or by history) and at least one of:
- Tachypnoea measured at triage (>60 bpm for age <1, >50 for 1-2 years of age, >40bpm for 2-4 years of age, and >30bpm for >4 years of age)
- Cough on exam or by history
- Increased work of breathing on exam
- Auscultatory finding (focal crackles, bronchial breathing, etc.) consistent with CAP
Who cannot take part
- Pneumonia previously (clinically) diagnosed within the past month (that was presumed to have resolved prior to the episode prompting the current visit to the ED)
- Children who present with ongoing fever after 4 days of amoxicillin, cefprozil, cefuroxime, levofloxacin, moxifloxacin or doxycycline are not eligible; as this duration of therapy with these drugs would normally be sufficient to treat bacterial CAP, a different approach would be required (ie. the care pathway as written might not be appropriate)
- Anatomic Lung Disease
- Chronic Lung Disease requiring home oxygen or home ventilation
- Congenital heart Disease (requiring specific medical treatment or with exercise restrictions),
- History of repeated aspiration/velopharyngeal incompetence
- Malignancy
- Children will be excluded if they have any of the following
- Cystic Fibrosis
- Bronchiectasis
- Immunodeficiency (primary, acquired or iatrogenic)
- Lung abscess within the past 6 months
- Children will not be eligible to participate more than once
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
In North America, up to 5% of preschoolers develop community-acquired pneumonia (CAP) every year. Pneumonia is the second-leading reason for paediatric hospitalization in both Canada and the US; approximately 20% of children hospitalized with CAP may need intensive care, which can result in significant morbidity. Given this burden of disease, it is critical that CAP is managed appropriately. Specific therapy for CAP is dependent on microbiologic aetiology, as bacterial disease will improve with antibiotic treatment.
The 2 groups in the trial
- The novel care pathway interventionTreatment being tested
The novel care pathway intervention will incorporate multiple factors to determine risk of bacterial CAP. At recruitment, POC CRP testing, and bioMérieux Spotfire testing of nasopharyngeal swabs (NPS) will identify those who are at appreciable risk and will receive a prescription for antibiotic treatment on day 0. Please refer to the Specimen Collection and Processing manual for more specific information on the collection process. Appreciable-risk participants will be referred back to the clinical team to be given amoxicillin, the current standard of care in Canada (those with penicillin allergy will presumably receive an appropriate substitution as per local guidelines). Low-risk participants will be discharged home without antibiotics.
- Control GroupExisting treatment, for comparison
Participants will be recruited in the ED and will be managed as per the treating clinician; the study team will not influence management
Treatment: Usual Care Alone
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- PromotIng Optimal Treatment for Community-acquired PNeumonia in EmErgency Rooms (PIONEERS): a Multicentre, Randomized, Open-labelled, Controlled, Clinical Trial
- Record updated
- 29 April 2026